Previous 10 | Next 10 |
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Exact Sciences Corporation 2022 Q4 - Results - Earnings Call Presentation
Exact Sciences ( NASDAQ: EXAS ), the maker of the Cologuard cancer screening test, traded ~2% lower post-market Tuesday after announcing in-line guidance for 2023. Revenue for the quarter jumped ~17% YoY to $553.0M as Screening revenue and Precision Oncology revenue stood at $403....
Exact Sciences press release ( NASDAQ: EXAS ): Q4 GAAP EPS of -$0.72 beats by $0.11 . Revenue of $552.9M (+16.7% Y/Y) beats by $27.29M . Total fourth quarter revenue of $553 million, an increase of 17% or 28% excluding COVID-19 testing, with Screening revenue of $404 m...
Exact Sciences Announces Fourth Quarter 2022 Results PR Newswire Reports record revenue, expects revenue of $2,265 -2,315 million and positive adjusted EBITDA for full year 2023 Fourth quarter and 2022 highlights Total fourth quarter revenue of $553 milli...
Summary Today, we zero in on Exact Sciences Corporation, best known for its "best of breed" non-invasive stool-based DNA screening test called Cologuard. Exact Sciences stock has soared 35% so far in 2023 thanks largely to an upward revision to fourth quarter guidance. Can the rally...
Summary Singular Genomics Systems is a unique opportunity to invest in a commercially-viable startup at the forefront of a rapidly expanding field. The company has adequate funding to maintain its current level of commercialization and sales activity for a few years. Capital gains c...
Exact Sciences ( NASDAQ: EXAS ) lost ~2% pre-market Friday after Credit Suisse downgraded the cancer test developer to Neutral from Outperform despite the company's recent outperformance in Q4 2022. Exact ( EXAS ), the company behind the Cologuard colorectal cancer screening t...
After a rough 2022, where the bear market destroyed the valuation of many growth stocks, there's been a bit of a reversal to start this year. Many stocks that took a beating last year are already up more than 30% in 2023, including Tesla (NASDAQ: TSLA) , Shopify (NYSE: SHOP) , and...
Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S. PR Newswire Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer MADISON, Wis. , Feb. 7, 2023 /PRNewswi...
Summary There are many types of investors. Here are three very famous but very different types of investors. Who do you identify with the most? Which investment strategy aligns with your very own? Who do you think is going to come ahead in 2023, as well as over the next 3, 5, and 10...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...